key: cord-0430202-jimdd18m
authors: Barsi, Szilvia; Papp, Henrietta; Urbelz, Alberto Valdeolivas; Tóth, Dániel J.; Kuczmog, Anett; Madai, Mónika; Hunyady, László; Várnai, Péter; Saez-Rodriguez, Julio; Jakab, Ferenc; Szalai, Bence
title: Computational drug repurposing against SARS-CoV-2 reveals plasma membrane cholesterol depletion as key factor of antiviral drug activity
date: 2021-09-10
journal: bioRxiv
DOI: 10.1101/2021.09.10.459786
sha: 08446f2184561460c857aedffdc9253cdd2fcbaa
doc_id: 430202
cord_uid: jimdd18m

Comparing SARS-CoV-2 infection-induced gene expression signatures to drug treatment-induced gene expression signatures is a promising bioinformatic tool to repurpose existing drugs against SARS-CoV-2. The general hypothesis of signature based drug repurposing is that drugs with inverse similarity to a disease signature can reverse disease phenotype and thus be effective against it. However, in the case of viral infection diseases, like SARS-CoV-2, infected cells also activate adaptive, antiviral pathways, so that the relationship between effective drug and disease signature can be more ambiguous. To address this question, we analysed gene expression data from in vitro SARS-CoV-2 infected cell lines, and gene expression signatures of drugs showing anti-SARS-CoV-2 activity. Our extensive functional genomic analysis showed that both infection and treatment with in vitro effective drugs leads to activation of antiviral pathways like NFkB and JAK-STAT. Based on the similarity - and not inverse similarity - between drug and infection-induced gene expression signatures, we were able to predict the in vitro antiviral activity of drugs. We also identified SREBF1/2, key regulators of lipid metabolising enzymes, as the most activated transcription factors by several in vitro effective antiviral drugs. Using a fluorescently labeled cholesterol sensor, we showed that these drugs decrease the cholesterol levels of plasma-membrane. Supplementing drug-treated cells with cholesterol reversed the in vitro antiviral effect, suggesting the depleting plasma-membrane cholesterol plays a key role in virus inhibitory mechanism. Our results can help to more effectively repurpose approved drugs against SARS-CoV-2, and also highlights key mechanisms behind their antiviral effect.

The newly emerged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), causing the coronavirus disease 2019 , has led to more than 222,000,000 infections and 4,600,000 deaths worldwide (Dong, Du, and Gardner 2020) . Identification of new therapeutic compounds against SARS-CoV-2 / COVID-19 is an urgent need until effective vaccination is worldwide available and given the emergence of SARS-CoV-2 strains showing immune evasion (McCallum et al. 2021) . The main therapeutic strategies include A) inhibiting key viral enzymes (like remdesivir (M. ); B) modulating the infected cells to decrease viral replication Bouhaddou et al. 2020) and C) modulating the over-activation of the immune system to treat late complications like "cytokine storm" (Cuccarese et al. 2020; Ragab et al. 2020; Olbei et al. 2021) . Repurposing already approved drugs for these indications is especially important as it allows a shorter time of approval for anti-SARS-CoV-2 treatment.

Comparing gene expression signatures of drugs and diseases have been previously shown to be an effective strategy to repurpose drugs for new therapeutic indications (Sirota et al. 2011 ).

The general principle of these studies is that a drug inducing an opposite gene expression signature to a disease signature can reverse the disease-related gene expression changes, thus the disease phenotype. This "signature reversal" principle has also been used to predict effective drugs against SARS-CoV-2 infection (Napolitano et al. 2020; Zhou et al. 2020; Hoagland et al. 2020) . However, these predictions lack, in most cases, mechanistic insight and experimental validation. Moreover, as infected cells activate adaptive antiviral pathways (like interferon pathway), inhibiting these pathways does not necessarily decrease viral replication.

In this study, we analysed transcriptomics data from in vitro SARS-CoV-2 infected cell lines and from cell lines treated with drugs showing anti-SARS-CoV-2 activity (effective drugs). Functional genomic analysis revealed shared transcription factor and pathway activity changes (eg.

increased activity NFkB and JAK-STAT pathways) in the infected and effective drug-treated cell lines. Similarity between infection signature and drug signature was predictive for in vitro effective drugs, contradictory to the classical "signature reversal" principle. Machine learning-based prediction of effective drugs identified SREBF1 and SREBF2 transcription factors, key regulators of lipid metabolism, as important factors of antiviral drug effect. Using a fluorescently labeled cholesterol sensor, we showed the decreased level of plasma-membrane cholesterol in cells treated with effective drugs, like chlorpromazine, confirming the effect of these drugs on cholesterol metabolism. We also identified amiodarone, a drug decreasing plasma-membrane cholesterol content, thus a potential in vitro effective drug. Using an in vitro SARS-CoV-2 infection assay, we demonstrated that the antiviral effect of amiodarone can be reversed by cholesterol supplement, underlying the relevance of decreased plasma-membrane cholesterol in the antiviral drug effect.

We analysed gene expression data from two recent studies (GSE147507 (Blanco-Melo et al. 2020 ) and GSE148729 (Wyler et al. 2021 )), where lung epithelial cancer cell lines (Calu-3 and A549) were infected with SARS-CoV-2. To identify infection-induced pathway and transcription factor (TF) changes, we used the PROGENy (Schubert et al. 2018; Holland, Szalai, and Saez-Rodriguez 2019) and DoRothEA (Garcia-Alonso et al. 2018 tools, respectively (more details in Methods).

PROGENy analysis showed increased activity of NFkB and TNFa pathways in both analysed cell lines, while the activity of JAK-STAT pathway increased more pronounced in infected Calu-3 cell lines ( Figure 1A ). DoRothEA analysis ( Figure 1B ) revealed strong activation of STAT, IRF and NFkB transcription factors, while cell growth-related transcription factors (E2Fs, Myc) showed decreased activity. Also SREBF1/2, key transcriptional regulators of cholesterol synthesis, showed decreased activity. STATs, IRFs and NFkB pathways / TFs play a key role in antiviral innate immunity (Seth, Sun, and Chen 2006) . Decreased activity of E2Fs and Myc (Ramana et al. 2000) and decreased synthesis of cholesterol (York et al. 2015) are also part of the physiological antiviral / interferon response.

To further analyse which upstream signalling pathways regulate the inferred TF activity changes, we used CARNIVAL (Liu et al. 2019 ), a signaling network contextualisation tool, which connects transcription factor activities to perturbations in signaling networks via integer linear programming (more details in Methods). We performed CARNIVAL analysis using inferred transcription factor activities from a SARS-CoV-2 infected cell line (GSE147507, Calu-3), and used RIG-I like receptors (DDX58 and IFIH1), key receptors for foreign RNA sensing (Rehwinkel and Gack 2020) , as main perturbation target. CARNIVAL results showed ( Figure 1C ), that activation of RIG-I like receptors by the dsRNA of SARS-CoV-2 can directly lead to the observed transcription factor activity changes, including activation of NFkB, IRFs and STATs and inhibition of SREBF2 and E2F4. Key identified intermediate nodes AKT1 and MAPK1 were already connected to coronavirus infection (Kindrachuk et al. 2015; Bouhaddou et al. 2020) , also suggesting that the observed TF changes are initiated by the RIG-I like receptors, thus corresponding to the antiviral response of the host cell.

In summary, our functional analysis of the gene expression changes in SARS-CoV-2 infected cell lines suggests that a large part of the induced pathway / transcription factor activity changes are adaptive, i.e. part of the physiological antiviral response. . Activities were calculated from differential expression signatures (infected -control) 

To compare infection and drug-induced signatures, we used a large compendium of drug-induced gene expression signatures from the LINCS-L1000 project (Subramanian et al. 2017 Riva et al. 2020; Weston et al. 2020; Heiser et al. 2020; Si et al. 2020; Touret et al. 2020; Ellinger et al. 2021; Jeon et al., n.d.) . We found an intersection of 47 drugs between LINCS-L1000 (available gene expression signatures) and ChEMBL dataset (in vitro effective drugs). To characterize drug-induced pathway and transcription activity changes, we analysed consensus drug signatures using PROGENy and DoRothEA.

PROGENy analysis showed strong activation of NFkB and TNFa pathways by several drugs, including niclosamide, perhexiline and digoxin ( Figure 2A ). Several drugs also strongly activated the JAK-STAT pathway (RTK inhibitors osimertinib and regorafenib). In case of TF analysis, we found similar patterns ( Figure 2B ) to the infection-induced signatures: increased activity of NFkB and STAT transcription factors and decreased activity of Myc/E2Fs transcription factors.

Interestingly, SREBF1/2 showed strongly increased activity for a large cluster of drugs, but As we found that, for several drug clusters, drug-induced TF activities showed positive correlation with SARS-CoV-2 induced TF activities, we were interested in the general similarity of drug and infection-induced gene expression signatures. To achieve this we calculated the signature similarity (Spearman's correlation coefficient, which has been previously shown to be an effective metrics to analyse signature similarity for the LINCS-L1000 data (Subramanian et al. 2017; Szalai et al. 2019) ) between all the 4,671 drug signatures from our LINCS-L1000 dataset and the infection signatures. We found that effective anti-SARS-CoV-2 drugs (ChEMBL dataset)

have higher similarity to infection signatures, than ineffective drugs / drugs with unknown efficacy ( Figure 2E , Mann-Whitney U test p value =<1e-200).

In summary, we found that known in vitro effective anti-SARS-CoV-2 drugs induce similar pathway and TF activity patterns, and appropriately similar gene expression signatures to virus infection signatures. We also identified two large clusters of drugs inducing strong activation of SREBF1/2 transcription factors, key regulators of cholesterol / lipid metabolism. 

drugs and known anti-SARS-CoV-2 drugs (ChEMBL drugs).

After identifying some general patterns in the gene expression signatures of in vitro effective anti-SARS-CoV-2 drugs, we investigated how well we can predict drug effectiveness using gene expression signatures.

As a first strategy, we simply used the previously calculated drug -infection signature similarity to predict effective drugs. Using these similarity values (predicted score) and the known in vitro effective drugs (ChEMBL dataset, true positive values) we performed ROC analysis ( Figure 3A ).

We found that similarity to infection signatures is predictive for effective drugs, i.e. drugs with high similarity to infection signature are more frequently effective ( Following this unsupervised prediction strategy, we also performed supervised, machine learning-based predictions. We used the drug-induced TF activities as features, and effective drugs from the ChEMBL dataset as positive examples, with Random Forest Classification as prediction algorithm. We set up a random subsampling based cross-validation scheme and evaluated the performance using ROC analysis (Methods). Our results showed a slightly improved performance compared to the unsupervised, similarity-based approach (mean ROC AUCs: 0.69 and 0.68, 0.66, 0.57, respectively for the machine learning and similarity based methods, paired t-test p-values between machine learning and similarity based methods:

1.85e-01, 1.29e-06, 1.75e-34 for GSE147507 A549, Calu-3 and GSE148729 Calu-3 signatures respectively, Figure 3C ). To gain some more mechanistic insight from the prediction of machine learning models, we analysed feature importances (Gini importance, Figure 3D ) of the Random Forest Regression models and found that SREBF1 and SREBF2 activity were the two most important features, followed by HNF4A, TFAP2A and TP63 transcription factors.

In summary, our two different prediction approaches showed reasonable performance to predict drugs with in vitro anti-SARS-CoV-2 activity, and also highlighted the importance of previously discussed SREBF1/2 transcription factors. Drug -SARS-CoV-2 signature similarities, and predicted probabilities of anti-SARS-CoV-2 activity is available in Supplementary Table 1. (Horton, Goldstein, and Brown 2002) . From this point of view, decreased SREBF activity during viral infection can lead to decreased cholesterol synthesis, which can inhibit the viral replication and/or viral entry (York et al. 2015) , thus can be considered as an adaptive response of the host cell ( Figure 4A ).

Interestingly, we observed a strongly increased SREBF activity in large clusters of effective drugs. To resolve this discordance, we hypothesized that these in vitro effective drugs directly decrease plasma membrane cholesterol ( Figure 4A ). In this case, drug induced decrease of plasma membrane cholesterol can contribute to the antiviral effect, while decreased cholesterol levels can activate SREBFs, thus explaining the observed increased activity of these TFs in our bioinformatic analysis.

To confirm this hypothesis, we performed high-throughput, automatic confocal microscopy 

As our experiments revealed that the selected drugs with in vitro anti-SARS-CoV-2 activity decreased the cholesterol content of plasma membrane, we were interested in whether decreased plasma membrane cholesterol levels could play a causal role in the antiviral effect, according to our assumptions ( Figure 4A ). To test this hypothesis, we performed in vitro SARS-CoV-2 viral infection assay with cholesterol rescue in Vero-E6 cells.

At first we tested whether the investigated drugs show anti-SARS-CoV-2 activity in our previously described experimental system (Konrat et al. 2020) . Briefly, Vero-E6 cells were co-treated with SARS-CoV-2 and the selected drugs (6 μM 

In this study, we analysed the gene expression signatures of in vitro SARS-CoV-2 infected cells and effective anti-SARS-CoV-2 drugs. Using functional genomic computational tools, we showed that both virus infection and drug treatment leads to similar changes of pathway and transcription factor activities, like activation of antiviral NFkB and JAK-STAT pathways. Signature similarity between infection and drug signature was predictive for drugs with in vitro anti-SARS-CoV-2 activity, contrary to the classical "signature reversal" hypothesis. Using machine learning models we effectively predicted anti-SARS-CoV-2 drugs, and predicted amiodarone as an in vitro antiviral compound. More detailed functional genomic analysis of TF activities revealed that SREBF1/2 TFs are strongly activated by large clusters of effective drugs.

Using a high-throughput confocal microscopy setup and quantitative image analysis we showed In summary, our study showed that in vitro SARS-CoV-2 infection and effective antiviral drugs lead to similar pathway and transcription activity changes. We found that gene expression signature similarity, and not the dissimilarity, predicts in vitro effective antiviral compounds, which can accelerate computational drug repurposing against infectious diseases, and we made the results of our predictions available for the research community (Supplementary Table 1 ). We also identified that plasma membrane cholesterol depletion plays an important role in the mechanism of action of several antiviral drugs, and that cholesterol replenishment inhibits the in vitro antiviral effect of amiodarone, thus our results also give mechanistic insight about the antiviral effect of repurposable drugs. In all gene expression datasets, we used (virus infected -control) contrasts for differential expression calculation, where the control condition was mock infection. Where gene expression data after multiple time points were available, we used 24 h post-infection data. Shared genes across all datasets were selected and further analyzed.

We used Level 5 gene expression profiles from the LINCS-L1000 dataset (Subramanian et al. 2017 ). We calculated consensus expression signatures for each drug (across different cell lines, concentrations and time points) using the MODZ method Subramanian et al. 2017 ). We matched LINCS-L1000 drugs with ChEMBL effective drug dataset (http://chembl.blogspot.com/2020/05/chembl27-sars-cov-2-release.html) using drug names and simplified molecular-input line-entry system (SMILES). Only measured (landmark) genes were used in the further analysis.

From previously calculated SARS-CoV-2 infection and effective drug-induced signatures, we inferred pathway activities using PROGENy (R package progeny, (Schubert et al. 2018; Holland, Szalai, and Saez-Rodriguez 2019) ) and transcription factor activities using DoRothEA ( 

We calculated similarities using Spearman's correlation between each virus infection-induced and each drug treatment-induced signature after selecting shared genes.

TF activity scores from drug treated cells were used to predict effective drugs against SARS-CoV-2 using Random Forest Classifier from scikit-learn Python library (Pedregosa et al. 2011 ). The model was trained with default parameters (100 trees) and with 100 different training sets. Training sets consisted of a 50% random sampling of effective drugs and non-effective drugs as well. The average importance of features (TFs) was computed (sum of feature importances, divided by the number of models). Predictive probabilities of drugs were also computed in each prediction and the mean of them was calculated (probabilities were summed for each drug and divided by the number of occurrences in validation sets).

We performed ROC analysis using scikit-learn Python library to evaluate similarity-based and machine learning-based predictions. Effective drugs against SARS-CoV-2 curated by ChEMBL and overlapping with drugs of the LINCS-L1000 dataset were used as the positive class. The negative class consisted of the part of drugs from the LINCS-L1000 dataset not considered as effective by ChEMBL. To compare machine learning-based and similarity-based methods ROC curves were computed for each different validation set (100) and signature similarity scores of the corresponding drugs were considered.

The cellular cholesterol sensor used in this study was the D4H domain ((Maekawa and Fairn 2015; Maekawa 2017)) fluorescently labeled with monomer Venus (mVenus) on its N-terminus.

To create the construct coding this sensor, we used a plasmid coding the bioluminescent version of the sensor (described in (Sohn et al. 2018 Measurements were performed at 30°C. Three independent measurements were made, with duplicate wells for each condition and 5 images/well taken for each time point.

All chemicals used for treatment were purchased from Sigma-Aldrich Merck (Germany).

Amiodarone HCl, chlorpromazine HCl, loperamid HCl and rosuvastatin calcium were dissolved in DMSO, stored at -20°C as 10 mM stock solutions and diluted in cell medium promptly before cell treatment to a final concentration of 10 μM. MβCD was stored as powder at 4°C and freshly dissolved in cell medium before treatment to a final concentration of 10 mM.

Images were segmented with Cellpose Python library (Stringer et al. 2021 

Amiodarone HCl (Sigma-Aldrich, Merck KGaA, Germany) was dissolved in DMSO (Sigma-Aldrich, Merck KGaA, Germany) and kept at -20 ℃. Chlorpromazine (in house synthesized based on (Galons et al. 1985) ) and loperamide HCl ( 

All analysis code to reproduce the results of this manuscript is available at https://github.com/comp-sys-pharm/SARS-CoV-2-cholesterol. 

Functional Characterization of Somatic Mutations in Cancer Using Network-Based Inference of Protein Activity

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

The Global Phosphorylation Landscape of SARS-CoV-2 Infection

Reversal of Cancer Gene Expression Correlates with Drug Efficacy and Reveals Therapeutic Targets

A Systems-Level Study Reveals Host-Targeted Repurposable Drugs against SARS-CoV-2 Infection

Functional Immune Mapping with Deep-Learning Enabled Phenomics Applied to Immunomodulatory and COVID-19 Drug Discovery

Identification of Required Host Factors for SARS-CoV-2 Infection in Human Cells

An Interactive Web-Based Dashboard to Track COVID-19 in Real Time

Footprint-Based Functional Analysis of Multi-Omic Data

A SARS-CoV-2 Cytopathicity Dataset Generated by High-Content Screening of a Large Drug Repurposing Collection

A Convenient Procedure for the Synthesis of Phenothiazine Drugs

Benchmark and Integration of Resources for the Estimation of Human Transcription Factor Activities

Transcription Factor Activities Enhance Markers of Drug Sensitivity in Cancer

A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug Repurposing

Identification of Potential Treatments for COVID-19 through Artificial Intelligence-Enabled Phenomic Analysis of Human Cells Infected with SARS-CoV-2

Modulating the Transcriptional Landscape of SARS-CoV-2 as an Effective Method for Developing Antiviral Compounds

Transfer of Regulatory Knowledge from Human to Mouse for Functional Genomics Analysis

SREBPs: Activators of the Complete Program of Cholesterol and Fatty Acid Synthesis in the Liver

Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs

Cell Host Response to Infection with Novel Human Coronavirus EMC Predicts Potential Antivirals and Important Differences with SARS Coronavirus

Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for Middle East Respiratory Syndrome Coronavirus Infection as Identified by Temporal Kinome Analysis

The Anti-Histamine Azelastine, Identified by Computational Drug Repurposing, Inhibits SARS-CoV-2 Infection in Reconstituted Human Nasal Tissue In Vitro

mRNA Expression Signatures of Human Skeletal Muscle Atrophy Identify a Natural Compound That Increases Muscle Mass

The Host Cell ViroCheckpoint: Identification and Pharmacologic Targeting of Novel Mechanistic Determinants of Coronavirus-Mediated Hijacked Cell States

Activation and Evasion of Type I Interferon Responses by SARS-CoV-2

Host Regulatory Network Response to Infection with Highly Pathogenic H5N1 Avian Influenza Virus

From Expression Footprints to Causal Pathways: Contextualizing Large Signaling Networks with CARNIVAL

Moderated Estimation of Fold Change and Dispersion for RNA-Seq Data with DESeq2

Domain 4 (D4) of Perfringolysin O to Visualize Cholesterol in Cellular Membranes-The Update

Complementary Probes Reveal That Phosphatidylserine Is Required for the Proper Transbilayer Distribution of Cholesterol

Connectivity Mapping (ssCMap) to Predict A20-Inducing Drugs and Their Antiinflammatory Action in Cystic Fibrosis

SARS-CoV-2 Immune Evasion by the B.1.427/B.1.429 Variant of Concern

Computational Drug Repositioning and Elucidation of Mechanism of Action of Compounds against SARS-CoV-2

SARS-CoV-2 Causes a Different Cytokine Response Compared to Other Cytokine Storm-Causing Respiratory Viruses in Severely Ill Patients

Scikit-Learn: Machine Learning in Python

Drug Repurposing: Progress, Challenges and Recommendations

The COVID-19 Cytokine Storm; What We Know So Far

Regulation of c-Myc Expression by IFN-Gamma through Stat1-Dependent and -Independent Pathways

RIG-I-like Receptors: Their Regulation and Roles in RNA Sensing

Limma Powers Differential Expression Analyses for RNA-Sequencing and Microarray Studies

A Large-Scale Drug Repositioning Survey for SARS-CoV-2 Antivirals

SARS-CoV-2 Requires Cholesterol for Viral Entry and Pathological Syncytia Formation

Perturbation-Response Genes Reveal Signaling Footprints in Cancer Gene Expression

Cytokine Systems Approach Demonstrates Differences in Innate and pro-Inflammatory Host Responses between Genetically Distinct MERS-CoV Isolates

Antiviral Innate Immunity Pathways

Human Organ Chip-Enabled Pipeline to Rapidly Repurpose Therapeutics during Viral Pandemics

Release of Severe Acute Respiratory Syndrome Coronavirus Nuclear Import Block Enhances Host Transcription in Human Lung Cells

Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data

PI(4,5)P2 Controls Plasma Membrane PI4P and PS Levels via ORP5/8 Recruitment to ER-PM Contact Sites

Drug and Disease Signature Integration Identifies Synergistic Combinations in Glioblastoma

Cellpose: A Generalist Algorithm for Cellular Segmentation

A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles

Why Do Pathway Methods Work Better than They Should?

Signatures of Cell Death and Proliferation in Perturbation Transcriptomics Data-from Confounding Factor to Effective Prediction

In Vitro Screening of a FDA Approved Chemical Library Reveals Potential Inhibitors of SARS-CoV-2 Replication

Drug-Induced Phospholipidosis Confounds Drug Repurposing for SARS-CoV-2

Integrated Intra-and Intercellular Signaling Knowledge for Multicellular Omics Analysis

SciPy 1.0: Fundamental Algorithms for Scientific Computing in Python

Remdesivir and Chloroquine Effectively Inhibit the Recently Emerged Novel Coronavirus (2019-nCoV) in Vitro

Cholesterol 25-Hydroxylase Inhibits SARS-CoV-2 and Other Coronaviruses by Depleting Membrane Cholesterol

Broad Anti-Coronaviral Activity of FDA Approved Drugs against SARS-CoV-2 in Vitro and SARS-CoV in Vivo

Transcriptomic Profiling of SARS-CoV-2 Infected Human Cell Lines Identifies HSP90 as Target for COVID-19 Therapy

Limiting Cholesterol Biosynthetic Flux Spontaneously Engages Type I IFN Signaling

Network-Based Drug Repurposing for Novel Coronavirus 2019-nCoV/SARS-CoV-2